Approach to the Patient With Treatment-resistant Acromegaly

Eva C. Coopmans, Aart J. Van Der Lely, Sebastian J.C.M.M. Neggers*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Although most tumors in patients with acromegaly are benign and are cured or controlled by surgery and/or first-generation somatostatin receptor ligands therapy, some can behave more aggressively and are resistant to these standard therapies. Acromegaly, if left untreated, is a rare and chronic disorder, commonly caused by a GH-producing pituitary adenoma and is associated with significant comorbidities and an increased mortality. Transsphenoidal surgery is considered the mainstay of acromegaly management, but medical therapy has an increasingly important role. However, disease activity is not fully controlled in a significant number of patients treated with surgery and/or high-dose first-generation somatostatin receptor ligand monotherapy. In these circumstances, therefore, repeated surgery, second-line medical therapy, and radiotherapy, alone or combined as multimodal therapeutic strategies should be considered, in a patient-centered perspective.

Original languageEnglish
Pages (from-to)1759-1766
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume107
Issue number6
Early online date28 Jan 2022
DOIs
Publication statusPublished - Jun 2022

Fingerprint

Dive into the research topics of 'Approach to the Patient With Treatment-resistant Acromegaly'. Together they form a unique fingerprint.

Cite this